In a report released today, Paul Choi from Goldman Sachs maintained a Sell rating on FibroGen (FGEN – Research Report), with a price target of $16.00. The company’s shares opened today at $3.19.
Choi covers the Healthcare sector, focusing on stocks such as PTC Therapeutics, FibroGen, and Ascendis Pharma. According to TipRanks, Choi has an average return of 7.7% and a 53.24% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for FibroGen with a $13.50 average price target.
See the top stocks recommended by analysts >>
FGEN market cap is currently $1.57B and has a P/E ratio of -4.91.
Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of FGEN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics. It focuses on hypoxia-inducible factor and connective tissue growth factor biology to develop innovative medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.
Read More on FGEN:
- FibroGen Tanks after Phase 3 Data in Pulmonary Fibrosis Disappoints
- FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
- FibroGen put volume heavy and directionally bearish
- FGEN Slides after DMD Candidate Fails In Phase 3 Trial
- FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
